Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
/in Cervical Cancer, Dendritic Cells, International PublicationsAdjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
/in Dendritic Cells, International Publications, Malignant MelanomaOncolytic virotherapy for urological cancers
/in International Publications, Newcastle Disease Virus, Prostate CancerIn Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
/in Colorectal Cancer, Hyperthermia, International PublicationsGenetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
/in International Publications, Newcastle Disease VirusDendritic cell-based cancer immunotherapy for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International PublicationsNewcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy
/in International Publications, Newcastle Disease VirusCancer Vaccines in Ovarian Cancer: How Can We Improve?
/in Dendritic Cells, International Publications, Ovarian CancerExtended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer